Thermo Fisher Scientific Inc. TMO
Verdict: Sell. Fair value $461 against a price of $621 on 6 Jan 2026, 26% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Revenue has been flat to slightly down since its 2022 peak ($44.91B in 2022 vs. $42.88B in 2024),....
Main risks
- Stagnating revenue growth post-COVID peak, with 1-year growth near zero and a decline from the 2022 high.
- Weak return on capital metrics (ROIC ~6.4%, est. ROIIC ~5.0%), suggesting inefficient capital allocation, a significant concern for an acquisitive company.
- Elevated leverage with an estimated Net Debt/EBITDA ratio over 4.0x (using total debt as a proxy), which could limit financial flexibility and increase risk.
- Intense competitive environment
- Valuation prices in optimistic scenario (limited margin for error)